Analyst
2048 VenturesCheck size: 2048 Ventures does not publish a standard current check-size range on its official site.
Lilly Iskold invests or supports investments through 2048 Ventures's published strategy: Be a high-conviction first institutional investor in exceptional founders at pre-seed and seed, helping companies move from earliest validation toward a durable seed-stage business.
Exceptional founding talent, an important problem, early technical or market insight and the ambition to create a category-defining company.
The firm is built for first-check pre-seed and seed investing; later-stage opportunities without an early company-building need are less aligned.
Lead with the founder insight, why now, earliest evidence, market size and the specific milestone a first institutional check will unlock.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Lilly Iskold is listed by 2048 Ventures as Analyst. Biology researcher with prior work at Humane Genomics and the New York Genome Center.